Sign in
BEAM Stock Price, Chart, Stats & News
Beam Therapeutics Inc.
Save
3.49B
Market cap
–
Current P/E
–
Forward P/E
BEAM chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | -126.14% |
Operating margin | -274.57% |
Pretax margin | -57.24% |
Net margin | -57.24% |
Effective tax rate | – |
ROA | -5.40% |
ROE | -7.31% |
D/E | 0.24x |
Interest coverage ratio | -36.06x |
BEAM valuation
P/E | – |
P/S | 16.17x |
P/B | 1.84x |
P/CF | -6.61x |
P/FCF | -6.28x |
P/OCF | -6.61x |
PEG | -0.37x |
EV multiple | -30.18x |
About
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia.
Similar securities
Based on sector and market capitalization
Report issue